Belmore Capital provides financing to Induce Biologics

01 February 2015
Client work

On February 27, 2015, Induce Biologics Inc., a pioneer in bone regenerative medicine research, announced that the company had closed a financing with Belmore Capital, including a minimum of $2 million, with an option to invest an additional amount into Induce as part of the company’s ongoing $10 million financing.

Belmore Capital is a Toronto-based venture capital firm with a presence in Palo Alto, California and an investor in technology and life sciences companies.

We advised Belmore Capital in this financing with a team that included Vanessa Grant and Michael Macaulay.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.
Related   Life Sciences, Mergers & Acquisitions, Private Equity

Related Insights & Resources

View all insights Related Insights & Resources
Articles
18 March 2019 Risks facing acquiring companies: liability to pay damages for EU competition law infringements committed by acquired businesses
Articles
02 August 2018 UK merger control - how (not) to respond to a request for information and other lessons
Client work
03 May 2018 Canadian Pharmacists Association invests in Pharmapod
Download or print PDF